[#item_full_content] Two hemp companies are challenging a recent U.S. Drug Enforcement Administration rule that designated a hemp-derived psychoactive compound as a Schedule I substance, saying the agency’s move was an unlawful overreach that contradicts Congress’ legalization of hemp. 
Read More
